

# Life science

Research & development

Application form

**United States** 



## **INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES**

## **APPLICATION FORM**

#### INTRODUCTION

The purpose of this application form is for us to find out who you are and to obtain information relevant to the cover provided by the BioSurance® R&D policy. Completion of this application form does not oblige either party to enter into a contract of insurance.

Insurance is a contract of utmost good faith. This means that the information you provide in this application form must be complete, accurate and not misleading. It also means that you must tell us about all facts and matters which may be relevant to our consideration of your application for insurance. Any failure by you in this regard may entitle us to treat this insurance as if it never existed. If a contract of insurance is agreed between you and us this application form will form the basis of the contract.

Important: Some of the cover provided by this policy is on a claims made basis. This means that a claim must be first made against the Insured and notified to us during the period of the policy to be covered and a claim wil not be covered if it arises out of any actual or alleged wrongful act occurring before the Retroactive Date.

#### HOW TO COMPLETE THIS FORM

Whoever fills out the form must be a principal, partner or director of the applicant firm and should make all the necessary enquiries of their fellow partners, directors and employees to enable all the questions to be answered.

If you require any extra space to complete the answers to questions contained within this application form please continue your response in the Additional Information section at the back of the form. Once you have completed the form please return directly to your insurance agent.

## **SECTION I: COMPANY DETAILS**

I.I Please provide the following details:

Insured company:

1.2

1.3

Contact name:		
Address:		
ZIP code:		
Telephone:	Email address:	
Fax:	Website:	
Please state when your company v	was established:	MM / DD / YY
Please briefly describe below the r	nature of your business activities:	
f you have a brochure, or company l	iterature, please attach to this form.	

If you have a copy of an up to date business plan, please attach to this form.    Section 2: Premises Details	1.4	Please outline below your business development plans for the next 12 months, including the number of products under development and the stage of development for each:				
SECTION 2: PREMISES DETAILS  2.1 Please provide below details of your premises:  PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:		If you have a copy of an up to date business plan, please attach to this form	n.			
SECTION 2: PREMISES DETAILS  2.1 Please provide below details of your premises:  PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:						
SECTION 2: PREMISES DETAILS  2.1 Please provide below details of your premises:  PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:						
SECTION 2: PREMISES DETAILS  2.1 Please provide below details of your premises:  PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:						
PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  PREMISES 2  Address:  ZIP code:  Details of usage:	1.5	Please state the number of employees:				
PREMISES I  Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:	SEC	CTION 2: PREMISES DETAILS				
Address:  ZIP code:  Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  ZIP code:  Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:	2.1	Please provide below details of your premises:				
Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		PREMISES I				
Details of usage (e.g. labs, storage, offices etc.):  PREMISES 2  Address:  ZIP code:  Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		Address:				
PREMISES 2  Address:  ZIP code:  Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:			ZIP code:			
Address:  ZIP code:  Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		Details of usage (e.g. labs, storage, offices etc.):				
Details of usage:  Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		PREMISES 2				
Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		Address:				
Please continue on a separate sheet if more than two premises are to be insured  2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:			ZIP code:			
2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:		Details of usage:				
2.2 Please provide details of the premises of your supply chain partners that carry out significant work on your behalf, including those where you require cover for damage to your property and those where you have a significant reliance on them for your business activities:						
Name and Address  Details of Usage	2.2	Please provide details of the premises of your supply chain partners those where you require cover for damage to your property and those	that carry out significant work on your behalf, including			
		Name and Address	Details of Usage			

SECT	Address  Address  TON 3: ACTIVITIES  To you directly work with, or store, 'yes', please provide further details sing, storing and disposal:	Are panels exterior or interior?	Type of Panel (Make, model, core material)  s materials at your premises?	Are products LPS or FMRC4880 approved	(1994) ? No
SECT	Address  TION 3: ACTIVITIES  To you directly work with, or store,	Are panels exterior or interior?	Type of Panel (Make, model, core material)  s materials at your premises?	Are products LPS or FMRC4880 approved	(1994) ? No
	Address	Are panels exterior	Type of Panel	Are products LPSI or FMRC4880	(1994)
2.4 If		Are panels exterior	Type of Panel	Are products LPSI or FMRC4880	(1994)
2.4 If		Are panels exterior	Type of Panel	Are products LPSI or FMRC4880	(1994)
2.4 If	any of the premises listed in 2.1 an	d 2.2 contain composite or	sandwich panels, please provide	details:	
	you have answered 'no' to any of the		rovide further details:		
	OTE: Assuming you have answered yes k for evidence for these before paying		it is important to keep records of al	l relevant inspections	as we ma
i)	Lifts, boilers, steam and pressure of the statutory requirements?	vessels inspected and approv	ved to comply with all	Yes	□No
h	Fitted with electrical installations electrician and any defect remedia		every 5 years by a qualified	Yes	No
	Heated by a conventional electric	·		Yes	No
	OTE: We may refuse to pay a claim i re not put into full and effective opera				
f)	Protected by fire and intruder alar	rms that are subject to an ar	nnual maintenance contract?	Yes	No
	Self contained with a lockable ent	rance door?		Yes	 ∏No
ĺ	In a good state of repair?	not near the vienney of any	Trois, screams or craal waters.	Yes	□No
C.	and have not previously suffered of the land area free from flooding and	Yes Yes	∐No ∏No		
,	Free from cracks or other signs o	f damage that may be due to	o subsidence, landslip or heave		
	concrete, metal, asbestos or any o		rial?	Yes	□No

2.3 Are all of the premises:

	lf '	'yes', please answer the following:		
	a)	What proportion of stock is temperature sensitive?		%
	b)	Are your fridges/freezers less than 3 years old? If 'yes', please go to question 3.2 c)	Yes	No
		If no, do you have a maintenance contract in place?	Yes	No
		If yes, does the maintenance contract provide free parts and labor?	Yes	No
		Does the maintenance contract contain a provision that an inspection takes place at least annually?  N/A	Yes	No
	c)	Is electricity delivered by underground cables, with no overhead power lines in the immediate vicinity?	Yes	No
	d)	Do all fridges / freezers have back up power generators?	Yes	No
		If 'yes', how many hours back up is provided?		Hours
	e)	Do you have an alarm system that activates if the temperature falls outside the prescribed range?	Yes	No
	f)	Is the alarm system monitored by a third party central station?	Yes	No
	g)	Is stock duplicated in more than one freezer on the same site?	Yes	No
	h)	Is stock duplicated in more than one freezer at different sites?	Yes	No
	i)	Do you have a formal Business Continuity Plan for a power outage or failure in storage arrangements?	Yes	No
3.3	Ar	re specialist couriers utilized for stock transport?	Yes	No
	lf '	'no', please provide details of the arrangements:		
3.4	Ple	ease state stock consignment values:		
•		Annual value Maximum value	of one cons	ignment
		Domestic:	or one cons	Билене
		Outside (domestic) country, but within the continent:		
		Elsewhere in the world:		
3.5		(ill you transport stock to areas where the government currently advises against travel? (yes', please provide details below:	Yes	No
3.6	Ar	re you involved with R&D of your own products?	Yes	
3.6		re you involved with R&D of your own products?  'no', please go to question 3.10.	Yes	
	lf '	·	Yes	No
3.7	If '	'no', please go to question 3.10.	Yes	No
3.7	If '	ease state your annual gross expenditure:  ease state what proportion of your annual gross expenditure is attributable to:  Fixed internal cost (including payroll):	Yes	%
3.7	If '	ease state what proportion of your annual gross expenditure is attributable to:	Yes	
3.7	If '	ease state your annual gross expenditure:  ease state what proportion of your annual gross expenditure is attributable to:  Fixed internal cost (including payroll):	Yes	%

	Supplier	name	Nature of reliance	Con	tingency plans	5
	lf 'no', please go to secti	ion 4.	r services provided to third parties?			Yes No
	If 'yes', please state the Location of client	e income received	Last complete financial year	Current	financial year	(estimate)
			Products Services	Products		Services
	Domestic:					
	Elsewhere in the w	orld:				
	Total:	_				
3.11	Please give details of	the 3 largest contr	acts that you have carried out in th	e last 3 years:		
	Client name	Client business	Nature of work undertaken for this contract	Your annual income from this contract	Start date	Completion date
					MM / YY	MM / YY
					MM / YY	MM / YY
					MM / YY	MM / YY
					MM / YY	MM / YY
					MM / YY	MM / YY
					MM / YY	MM / YY
					MM / YY	MM / YY
3.12	What approximate per	rcentage of your in	come, in your current financial year, v	will be paid to sub-cor	tractors?	%
3.13	Will sub-contractors	carry the following	insurance:			
	a) Products liability fo	r CMOs?				Yes No
	b) Errors and Omission	ons for CROs, con	tract research service providers and	other consultants?		Yes No
	c) Medical malpractice conducting your cli		vernment liability) for clinical investi	gators		Yes No
3.14	Will your products be	e marketed for hur	man consumption in the next 12 mc	onths?		Yes No
	If 'no', please go to seco	tion 4.				
	If 'yes', please attach li	terature for each of	these products, including brochures, to	echnical literature, sale	conditions.	

3.16	Are these products:		
	a) Vaccines?	Yes	No
	b) Gene therapy?	Yes	No
	c) Cell therapy?	Yes	No
	d) Acutane, amenorone forte, bupropion, canthaxanthin, cisapride, danthron, debendox, DEHP, dexfenfluramine, diazepines, dicyclomine, diethylstilbestrol (DES), dioxins, ephedrine, fenfluramine, fibrates, germanium, halogenated 8, hydroxy quinolines, hydroquinone, isotretinoin, lotronex, l-tryptophan, methylphenidate, nefazodone, oxazepines, paxil, pertussis vaccine, phenfluramine, phentermine, phenylpropanolamine (PPA), piper methysticum, primodos, prozac, remoxipride, retinoids, risperidone, serzone, silicone gel used as part of an injection or as part of an implantable device, statins, swine-flu vaccine, thalidomide, thiazepines, thimerosol or thimersal, tretinoin, troglitazone, tryptophan?	Yes	□No
	e) Implantable medical devices?	Yes	No
	f) Skin whitening products?	Yes	No
	g) Birth control products or devices?	Yes	No
ı	If 'yes' to any of the above, please provide details:		
3.17	Could the failure of these products or services result in:		
	a) Loss of life or injury to a person?	Yes	No
	b) Damage or destruction to physical property?	Yes	No
	c) Significant third party financial loss?	Yes	No
	If 'yes' to any of the above, please provide details:		
3.18	Is the delivery of these products and services time critical to the third parties using them (such as a clinical trial)?  If 'yes', please provide details:	Yes	No

SEC	CTION 4: CONTRACT MANAGEMENT			
4.1	Is all work carried out (by you, or for you) under a written contract?	Y	es	No
4.2	Are all contracts reviewed by independent, qualified legal advisers?	Y	es	No
	If 'no', please outline the procedures used for developing and reviewing contracts:			
4.3	Are rights of recourse retained against CMOs, CROs, clinical investigators and all other supply chain partners?	Y	es	No
	If 'no', please explain why:			$\neg$
				_
4.4	In your written contracts do you ever accept liability for consequential loss or financial damages greater than the value of the contract?	Y	es	No
	If 'yes', please provide details:			_
				_
4.5	Do your written contracts ever contain 'Hold Harmless' or 'Indemnification' clauses in which you accept liability for loss of life, injury, property damage, or financial losses in circumstances other than where they are caused by your negligence?	Y	es	No
	If 'yes', please provide details:			
4.4				
4.6	In your written contracts, do you ever provide guarantees of products or services?	Y₁	es	No
	If 'yes', please provide details:			
				_
				_

## **SECTION 5: CLINICAL TRIALS**

Only complete this section if you require cover for clinical trials.

In respect of each of the clinical trials listed below, please attach the following (in English):

- a) Trial Protocol
- b) Patient Information
- c) Patient Informed Consent form
- d) A list of the Clinical Investigator sites
- 5.1 Please provide below details of completed trials for which cover is required:

Protocol number and description	Date treat	ment completed	Num	ber of subjects	Country
	MM /	DD / YY			
	MM /	DD / YY			
	MM /	DD / YY			
	MM /	DD / YY			
Please provide below the details primary cover is required:	of ongoing trials, o	r trials that are expe	cted to c	ommence in the ne	ext 12 months, for
Protocol number and description	Start date	e Expected en	d date	Number of subjects	s Country
	MM / DD /	YY MM / DD /	YY		
	MM / DD /	YY MM / DD /	YY		
	MM / DD /	YY MM / DD /	YY		
	MM / DD /	YY MM / DD /	YY		
primary insurance policy will be i	Start date	Expected end date	is require Numb of subj	ed: Der Country	/ Insurer and po
primary insurance policy will be i	n place and therefo	re excess cover only  Expected  end date	is requir	ed: Der Country	/ Insurer and po
primary insurance policy will be i	n place and therefo	re excess cover only  Expected	is requir	ed: Der Country	/ Insurer and po
primary insurance policy will be i	Start date	Expected end date	is requir	ed: Der Country	/ Insurer and po
primary insurance policy will be i	Start date  MM / DD / YY  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	/ Insurer and po
Please provide below the details of primary insurance policy will be in the Protocol number and description.  Are you the sponsor in respect of the provided in the sponsor in respect to the sponsor in	Start date  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	/ Insurer and po
Protocol number and description  Are you the sponsor in respect of	Start date  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	Insurer and po number fo underlying po
Protocol number and description  Protocol number and description  Are you the sponsor in respect of	Start date  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	Insurer and po number fo underlying po
Protocol number and description  Are you the sponsor in respect of	Start date  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	Insurer and po number fo underlying po
primary insurance policy will be i	Start date  MM / DD / YY	Expected end date  MM / DD / YY  MM / DD / YY  MM / DD / YY	is requir	ed: Der Country	Insurer and po number fo underlying po
Protocol number and description  Are you the sponsor in respect of 'no', please state the nature of	Start date  MM / DD / YY  of each of the clinical your interest:	Expected end date  MM / DD / YY  Al trials listed above?	Numl of subj	ed: Der Country	Insurer and po number fo underlying po
Protocol number and description  Are you the sponsor in respect of the first of the first of the sponsor in respect of the first of the sponsor in respect of the first of the sponsor in respect of the	Start date  MM / DD / YY  of each of the clinical your interest:	Expected end date  MM / DD / YY  Al trials listed above?	Numl of subj	ed: Der Country	Insurer and pornumber for underlying po
Protocol number and description  Are you the sponsor in respect of	Start date  MM / DD / YY  of each of the clinical your interest:	Expected end date  MM / DD / YY  Al trials listed above?	Numl of subj	ed: Der Country	Insurer and pornumber for underlying po

5.6	In respect of the clinical trials listed above, will any of the following be tested:		
	a) Vaccines?	Yes	No
	b) Gene therapy?	Yes	No
	c) Cell therapy?	Yes	No
	d) Acutane, amenorone forte, bupropion, canthaxanthin, cisapride, danthron, debendox, DEHP, dexfenfluramine, diazepines, dicyclomine, diethylstilbestrol (DES), dioxins, ephedrine, fenfluramine, fibrates, germanium, halogenated 8, hydroxy quinolines, hydroquinone, isotretinoin, lotronex, l-tryptophan, methylphenidate, nefazodone, oxazepines, paxil, pertussis vaccine, phenfluramine, phentermine, phenylpropanolamine (PPA), piper methysticum, primodos, prozac, remoxipride, retinoids, risperidone, serzone, silicone gel used as part of an injection or as part of an implantable device, statins, swine-flu vaccine, thalidomide, thiazepines, thimerosol or thimersal, tretinoin, troglitazone, tryptophan	Yes	No
	e) Implantable medical devices?	Yes	No
	f) Skin whitening products?	Yes	No
	g) Birth control products or devices?	Yes	No
	If 'yes' to any of the above, please provide details:		
5.7	In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the research subjects under 16 years?  If 'yes', please provide details:	Yes	No
5.8	In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the research subjects women of child bearing age?  If 'yes', please provide details:	Yes	No
5.9	Are all clinical trials conducted in accordance with all relevant local laws and regulations?  If 'no', please explain why:	Yes	No

5.10	In respect of all completed and ongoing trials, have you:		
	a) Made all necessary filings?	Yes	No
	b) Received all required authorisations?	Yes	No
	c) Had the protocol approved by an independent Ethics Committee?	Yes	No
	If 'no' to any of the above, please explain why:		
5.11	Do you ever act as both trial sponsor and clinical investigator?	Yes	No
	If 'yes', please provide details:		
F 12			□ No
5.12	Have you stopped or suspended any clinical trials for safety reasons?	☐ Yes	□ INO
	If 'yes', please provide details:		
5.13	Have any research subjects suffered death, injury, disease or illness (whether physical or mental)		
	as a result of participation in a clinical trial sponsored by you, in the past 5 years?	Yes	No
	If 'yes', please provide details:		
SEC	TION 6: COVER LIMITS & SUMS INSURED		
6.1	Would you like cover for damage to your property?	Yes	No
	If 'no', please go to question 6.7.		
	If yes, please attach information regarding the value of the following property, including estimated maximum v	values at risk at	: any
	one time where applicable, at the premises listed in question 2.1 and 2.2: a) Buildings		,
	b) Tenants improvements, fixtures & fittings c) Laboratory equipment		
	d) Fixed electronic equipment		
	e) Portable electronic equipment f) Lab consumables and R&D Stock (including the cost of materials and other re-creation costs)		
	g) Third party stock in your custody and control h) Research animals (showing the total value and the estimated maximum value of a single animal)		
	i) Any other property not listed above		

6.2	Would you like the policy to cover any	of the following:		
	a) Spoilage of perishable stock?			Yes No
	b) Pollution or contamination?			Yes No
	c) Machinery breakdown?			Yes No
	d) Property in transit?			Yes No
	e) Terrorism?			Yes No
	f) Ideologically motivated attack (that is an act of terrorism by the government			Yes No
6.3	Would you like business interruption of	over?		Yes No
	If 'yes', please state the 'First Loss' sum	n insured required:		
6.4	Please state the sublimits required for listed in question 2.2:	business interruption folic	owing damage at the premises	of your supply chain partners
	Supply chain partne	r name	Business inte	erruption sublimit
6.5	Please state the indemnity period requ	ired (6 - 24 months):		Months
6.6	Would you like cover for General Liabi	lity?		Yes No
	If 'yes', please state the limit of liability	required:		
6.7	Would you like cover for products and	services liability?		Yes No
	If 'yes', please state the limit of liability	required:		
SEC	CTION 7: CLAIMS EXPERIENCE	& INSURANCE HIST	ORY	
7.1	Please provide details of your current i	nsurance:		
	Туре	Expiry date	Retroactive date	Insurer
	Property and business interruption:	MM / DD / YY	N/A	
	General Liability:	MM / DD / YY	N/A	
	Products liability:	MM / DD / YY	MM / DD / YY	
	Errors and Omissions:	MM / DD / YY	MM / DD / YY	
	Clinical trials:	MM / DD / YY	MM / DD / YY	

- 7.2 Regarding all of the types of insurance to which this application form relates, AFTER ENQUIRY:
  - a) are you aware of any loss or damage, whether insured or not, that has occurred to any of the Companies to be insured (or to any existing or previous business of the partners or directors of any of the Companies to be insured) within the last 5 years, or
  - b) are you aware of any circumstances which may give rise to a claim against any of the Companies to be insured or any partners or directors thereof, or
  - c) have any claims or cease and desist orders been made against any of the Companies to be insured, or partners or directors thereof, or
  - d) have any partners or directors of the Companies to be insured been found guilty of any criminal, dishonest or fraudulent activity or been investigated by any regulatory body?

With reference to questions a, b, c and d above:

If the answer to the above is 'yes', then please attach full details including an explanation of the background of events, the maximum amount involved / claimed, the status of the claim(s) or circumstance(s) and any reserve(s) or payment(s) made by you and / or by Insurers, and the dates of all developments and payments.

### **SECTION 8: DECLARATION**

- I declare that after proper enquiry the statements and particulars given above are true and that I have not mis-stated or suppressed any material fact.
- I agree that this application form, together with any other material information supplied by me shall form the basis of any
  contract of insurance effected thereon.
- · I undertake to inform Underwriters of any material alteration to these facts occurring before the completion of the contract.

Signed:	Full name:		
Position held at insured:		Date:	MM / DD / YY

ADDITIONAL INFORMATION:	7